February 4, 2020

Mark A. Goldsmith
Chief Executive Officer
Revolution Medicines, Inc.
700 Saginaw Drive
Redwood City, CA 94063

       Re: Revolution Medicines, Inc.
           Amendment No.1 to Registration Statement on Form S-1
           Filed February 3, 2020
           File No. 333-235968

Dear Dr. Goldsmith:

      We have reviewed your amended registration statement and have the
comments. In some of our comments, we may ask you to provide us with
information so we
may better understand your disclosure.

       Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe our comments apply to your facts
circumstances or do not believe an amendment is appropriate, please tell us why
in your

       After reviewing any amendment to your registration statement and the
information you
provide in response to these comments, we may have additional comments.

Amendment No. 1 to Form S-1 filed February 3, 2020

Report of Independent Registered Public Accounting Firm, page F-2

1.     We note that your amended Form S-1 has been updated to reflect a
1-for-4.8661 reverse
       stock split of your common stock and redeemable convertible preferred
stock to be
       consummated prior to the effectiveness of your planned initial public
offering, which was
       approved by your Board of Directors on January 30, 2020. Please address
the following:
         Please ensure that your auditors provide reports that are fully
compliant with Rule
           2.02 of Regulation S-X, including the date of the accountants
         Please ensure that your auditors provide consents that are fully
compliant with Item
           601 of Regulation S-K, including the date of their consent.
 Mark A. Goldsmith
Revolution Medicines, Inc.
February 4, 2020
Page 2

       You may contact Bonnie Baynes at 202-551-4924 or Lisa Vanjoske at
202-551-3614 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Sonia Bednarowski at 202-551-3666 or Dietrich King at 202-551-8071 with
any other

FirstName LastNameMark A. Goldsmith                       Sincerely,
Comapany NameRevolution Medicines, Inc.
                                                          Division of
Corporation Finance
February 4, 2020 Page 2                                   Office of Life
FirstName LastName